{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 41,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "before_after",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a before-after framing to show goal alignment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/6",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.13,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16cc99be-3f90-455f-abfb-774469af32cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.08,
        "y": 0.23
      },
      "kind": "framework",
      "text": "Target",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e412b0-26a4-4f5b-91bf-f4efc47d3a87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.26,
        "x": 0.62,
        "y": 0.44
      },
      "kind": "list",
      "text": "Initiated Phase 3 CYPRESS trial in MSA patients with symptomatic nOH in Q1'23\nSubmitted orphan drug designation request in early 2023\nAnticipate completing CYPRESS enrollment in 2H'24",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ca7f1ad-d390-4340-a5b6-bd3678c5c218",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.26,
        "x": 0.1,
        "y": 0.44
      },
      "kind": "list",
      "text": "Initiate Phase 3 CYPRESS trial in MSA patients with symptomatic nOH in Q1'23\nSubmit orphan drug designation request in early 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c48bc21e-19ca-4998-86c0-96f556835207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Progress Against 2023 Ampreloxetine Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c45f5b7-b9ab-422b-af3a-2eef8b47c83f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "Milestones Achieved with CYPRESS Study",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "664e1a83-8e57-4d54-8aff-cc49e86f29e2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "f8137d47-87e0-419b-98b0-b8a30c6c5079",
      "evidence": "Initiated Phase 3 CYPRESS trial in MSA patients with symptomatic nOH in Q1'23",
      "confidence": 0.7
    },
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "09f8b7d6-79db-4525-aa40-08a43f37aa49",
      "evidence": "Progress Against 2023 Ampreloxetine Targets",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "81291ad1-0188-423c-97b3-cb9c3b356665",
      "evidence": "Visual comparison of targets vs progress using a directional arrow.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 5,
      "beatId": "18f97180-6c3c-4b05-a378-979222504b06",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Before-After",
      "beatSlug": null,
      "evidence": "Multiple slides show progress and growth using before-after comparisons.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}